康泰生物(300601.SZ)：五联疫苗开启Ⅲ期临床试验

Core Viewpoint - Kangtai Biological (300601.SZ) has announced that its wholly-owned subsidiary, Beijing Minhai Biotechnology Co., Ltd., has completed the preparation for Phase III clinical trials of a pentavalent vaccine, which has now officially commenced with the successful enrollment of the first subject [1] Group 1 - The pentavalent vaccine is designed to prevent invasive infections caused by diphtheria, tetanus, whooping cough, poliomyelitis, and Haemophilus influenzae type b [1] - The vaccine offers advantages such as reducing the number of injections for infants and enhancing compliance among parents and infants regarding vaccinations [1]